Dyne Therapeutics, Inc. Proceeds from Common Stock Issued
Dyne Therapeutics, Inc. (DYN) reported Proceeds from Common Stock Issued of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-07-29
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $0.00.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2025 was $140.65M, a 43.71% increase from fiscal 2024.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2024 was $97.87M, a 86.89% increase from fiscal 2023.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $52.37M, a 42.07% increase from fiscal 2022.
- Dyne Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $36.86M.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $0.00 derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $0.00 derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $377.70M 10-K · filed 2026-03-02 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $140.65M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $140.65M 10-Q · filed 2025-11-05 | $140.65M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-07-31 | $215.80M 10-K · filed 2026-03-02 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $140.65M 10-Q · filed 2026-07-29 | $140.65M derived: sum of 3 quarters · filed 2026-07-29 | $140.65M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $140.65M 10-Q · filed 2026-05-11 | $140.65M derived: sum of 2 quarters · filed 2026-05-11 | $140.65M derived: sum of 3 quarters · filed 2026-05-11 | $164.90M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $24.25M derived: sum of 3 quarters · filed 2026-03-02 | $97.87M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $24.25M derived: sum of 2 quarters · filed 2025-11-05 | $97.87M 10-Q · filed 2025-11-05 | $97.87M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $24.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $97.87M 10-Q · filed 2025-07-28 | $97.87M derived: sum of 3 quarters · filed 2026-03-02 | $97.87M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $73.62M 10-Q · filed 2025-05-08 | $73.62M derived: sum of 2 quarters · filed 2026-03-02 | $73.62M derived: sum of 3 quarters · filed 2026-03-02 | $97.76M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.00K derived: sum of 2 quarters · filed 2026-03-02 | $24.14M derived: sum of 3 quarters · filed 2026-03-02 | $52.37M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $24.14M derived: sum of 2 quarters · filed 2024-11-12 | $52.37M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $24.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $52.37M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $28.23M 10-Q · filed 2024-05-02 | ||||
| 2022-12-31 | $36.86M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |